Many clinical decisions are made daily based on the laboratory results generated within the clinical microbiology laboratory. Despite advances in laboratory methods that have increased automation and simplicity in generating laboratory results, consultation and review of the results with a microbiologist is still often necessary prior to reporting the final outcome of testing. To determine the most common reasons for and outcomes of consultation, we surveyed attending microbiologists and pathology residents covering the microbiology service at an urban academic center. Respondents were asked to supply information concerning the question raised by microbiology or clinical staff, the response by the clinical microbiology attending, and the ultimate resolution of the issue. A total of 29 complete consultations was reported over a 10-day period in February 2017. The nature of the consults was as follows: 15 (51.7%) concerned guidance related to the identification or susceptibility testing of clinical isolates, seven (24.1%) involved recommendations for additional testing (including send-out testing), six (20.7%) involved direct recommendations regarding antimicrobial therapy, and one (3.5%) involved enhanced monitoring and hospital infection control. Eighteen (62.1%) of the consults were initiated by microbiology technologists directly or during microbiology rounds, and nine (31.0%) were initiated by the clinicians caring for the patients. Two (6.9%) consults came from infection control. The consults ranged across a variety of laboratory sections, with the majority coming from bacteriology and virology. Twenty-two (75.9%) consults involved bacterial cultures and six (20.7%) pertained to viral testing. Within bacteriology, four consults (18.2% of the total bacteriology consults) were regarding test results indicating organisms with multidrug resistance. In virology, three of the consults (50% of the total virology consults) were specifically concerning HIV testing interpretation and guidance on follow-up testing. The direct clinical outcomes of the consults were broken down into four broad categories: directing antimicrobial therapy (n = 11, 37.9% of total consults), performing additional testing and microbiological workup (n = 8, 27.6%), removing infected devices (n = 2, 6.9%), and implementing infection control practices (n = 1, 3.5%). There were seven consults (24.1%) with an unknown or unclear direct clinical outcome. Overall, 22 of the 29 consults, or 75.9%, directly influenced patient care and management. In summary, most of the consults surveyed in this study were regarding bacterial culture results, and most consults occurred between laboratory technologists and the microbiologist on duty. It was also common for the microbiologist to consult directly with the clinical team (31.0% of consults). Limitations of this study include the short time frame as well as a likely underestimation of consults performed. Nonetheless, this study highlights the diversity of microbiology consultations performed by attending pathologists and the frequency with which these lead to impactful clinical decisions that directly influence the management of patients. Background: Changes in local cytokine levels accompany immune-mediated anti-tumor responses. However, cytokine responses are challenging to measure systemically, outside the tumor microenvironment. The lack of sensitivity in the sub-pg/mL range with existing assays is an obstacle in developing peripheral blood-based biomarkers for the field of immuno-oncology. The objective of this study was to clinically validate a new ultra-sensitive immunoassay platform with EDTA plasma patient specimens for eventual translation as a blood-based biomarker in immuno-oncology. Methods: Here, we describe the validation of ultra-sensitive single molecule array (Simoa) assays for IL-2, IL-6, IL-10, and IFNγ. Simoa cytokine assays have been carried out using serum but no studies have been carried out using plasma, which is more readily processed and prevents platelet activation, which can alter cytokine levels ex vivo. Ninety patient EDTA plasma specimens were obtained from excess CBC material. A subset of patient samples used was expected to be enriched for high endogenous cytokine levels by selecting for patients with high CRP levels. Up to 2.5 mL of whole blood was centrifuged at 2,000 x g for 15 minutes, and the supernatant plasma was then aliquoted and stored at -80°C. Either 29 uL (IL-6, IL-10) or 42 µl (IL-2, IFNγ) of thawed plasma was used for each Simoa assay. Simoa assays were performed using antibody pairs to form enzyme-labeled immunocomplexes on beads and were detected using single molecule counting with the HD-2 Analyzer (Quanterix, Lexington, MA). We evaluated various analytical parameters (linearity, precision, accuracy, lower limit of quantification, cross-reactivity, interferences) of the assay and assessed analyte stability to optimize for eventual clinical implementation. Results: The Simoa assays for IL-2, IL-6, IL-10, and IFNγ were both linear and precise. The lower limit of quantitation was 0.01 pg/mL for IL-6 and IL-10, and 0.04 pg/ mL for IL-2 and IFNγ. None of the four cytokine assays cross-reacted with up to 1,000 pg/mL recombinant protein. All analytes were stable in EDTA plasma at room temperature for up to six hours with the exception of IL-6; levels decreased by approximately 10% at six hours.
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There was no interference from hemolysis, icterus, and lipemia. Vigorous handling of whole blood specimens and transport by pneumatic tube did not significantly affect analyte levels. Conclusions: IL-2, IL-6, IL-10, and IFNγ are largely stable in EDTA plasma at room temperature for up to four hours after blood draw. Lower limits of quantitation by Simoa surpass those reported for ELISAs by an average of 722-fold for the four analytes measured. Simoa immunoassays are a robust technique to measure ultra-low concentrations of cytokines with high precision. Simoa cytokine immunoassays represent a promising approach for monitoring anti-tumor immune responses in peripheral blood. ) for treatment of acute lymphoblastic leukemia, lymphoma and osteosarcoma. MTX is primarily eliminated by the kidneys, and prolonged exposure to high concentrations leads to nephrotoxicity. Accurate measurement of plasma MTX concentration is crucial to coordinate the timing and dosage of leucovorin, and to determine when patients can be safely discharged. Currently, we measure MTX via the TDx Methotrexate II assay (Abbott Laboratories, Abbott Park, IL), which will unfortunately be discontinued in June 2017. Previously we validated the ARK Methotrexate assay (ARK Diagnostics, Sunnyvale, CA) on our Roche cobas 6000 analyzer and found that the ARK assay had poor precision at low concentrations. In an attempt to improve the precision of the assay we increased sample volume and concomitantly reduced reagent volume. Objective: Our study objective was to assess the precision of the ARK Methotrexate assay on low concentration samples (<0.3 mmol/L) on the Roche cobas 6000 analyzer by increasing sample volume and reducing reagent volume. Methods: We conducted method comparison and limit of quantitation (LOQ) studies of the ARK Methotrexate assay approved by the Food and Drug Administration, a laboratory modified ARK Methotrexate assay, and the TDx assay. For the method comparison, patient samples with MTX concentrations ranging from 0.02 to 0.77 mmol/L were analyzed on all three assays. The LOQ was determined by assaying five serum specimens spiked with MTX from pooled patient samples at final concentrations ranging from 0.03 to 0.3 mmol/L once daily for 17 days, and LOQ calculated by plotting the CV against the mean and fitting a curve to the data using EP Evaluator. Results: The method comparison yielded equations (95% confidence intervals) of unmodified ARK = 1.006(0.941 to 1.070)TDx + 0.018(-0.004 to 0.040), r = .9859, modified ARK = 0.895(0.829 to 0.96)TDx + 0.031(0.008 to 0.054), r = .9826. At low concentrations (<0.25 mmol/L), the modified ARK assay performed slightly better. The LOQ (20% CV) of the unmodified ARK assay was 0.06 mmol/L. The LOQ of the modified ARK assay could not be calculated as the CV was <20% at all concentrations tested. The LOQ for the TDx could not be calculated due to wide confidence intervals of the fitted CV. At a target concentration of 0.1 mmol/L the measured CVs were 12.4% (TDx), 6.0% (unmodified ARK) and 3.6% (modified ARK). At a target concentration of 0.03 mmol/L the measured CVs were 23.6% (TDx), 44.1% (ARK), and 14.1% (modified ARK). Conclusions: Our modification of the FDA-approved ARK assay on the Roche cobas 6000 analyzer demonstrated similar low concentration accuracy but improved precision. Despite this improvement, our results also support that the unmodified ARK assay is suitable for monitoring MTX at the medical decision points used at our institution. Background: Lead exposure adversely affects cognitive, behavioral, and psychological development, particularly in children. In adults, occupational or environmental lead poisoning can cause nervous system toxicity, renal dysfunction, and hypertension, but the early symptoms are often nonspecific. Blood lead level (BLL) measurements assess cumulative lead exposure and are widely used as lead poisoning indicators. In addition to individuals at risk for lead poisoning, the Centers for Disease Control and Prevention (CDC) recommend screening of BLL in children based on risk assessment. In 2012, the CDC reduced the criteria for elevated BLL from 10 ug/dL to 5 ug/dL for children under the age of 6. No level of lead is considered to be safe in children. Therefore, evidence-based improvements on the criteria for evaluating elevated BLL can ensure the continuous decline of BLL and assist with monitoring and prevention of lead contamination events.
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